PROBIOTICS FOR INFANTILE COLIC: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i5.1684Keywords:
Colic, Gut, Infat, Lactobacillus, ProbioticsAbstract
Colic in infants is a self-limiting ailment; nonetheless, it can be unpleasant for parents and tough for doctors to treat. Approximately 20% of infants suffer from infantile colic, which typically reaches its peak between 5 and 6 weeks of age. The challenge for the medical staff is in making an accurate diagnosis and coming up with a treatment plan for the ailment. In order to give doctors with a full grasp of the problem, current advancements, and future possibilities, the purpose of this review article is to outline the pathophysiology of infantile colic, as well as the treatment choices and prognosis for the condition. There are a few potential treatments for infantile colic, the most prominent of which is the use of probiotics, specifically lactobacillus. The most compelling evidence in support of probiotics comes from the prevention or treatment of these five conditions: necrotizing enterocolitis, acute infectious diarrhea, acute respiratory tract infections, antibioticassociated diarrhea, and newborn colic. Inhibition of bacterial adhesion, improvement of mucosal barrier function, manipulation of both the innate and adaptive immune systems, release of bioactive metabolites, and control of the enteric and central nervous systems are some of the mechanisms of action that probiotics exhibit.
References
Korterink J, Devanarayana NM, Rajindrajith S, et al. Childhood functional abdominal pain: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2015;12(3):159–71.
Kliegman R. M; et al. Nelson Textbook of Pediatrics. Philadelphia: Elsevier Saunder; 2016.
Sarasu JM, Narang M, Shah D. Infantile Colic: An Update. Indian Pediatr [Internet] 2018;55(11):979–87. Available from: https://doi.org/10.1007/s13312-018-1423-0
Huang Y, Tan SY, Parikh P, Buthmanaban V, Rajindrajith S, Benninga MA. Prevalence of functional gastrointestinal disorders in infants and young children in China. BMC Pediatr. 2021;21:1–7.
Wolke D, Bilgin A, Samara M. Systematic review and meta-analysis: fussing and crying durations and prevalence of colic in infants. J Pediatr. 2017;185:55–61.
Koppen IJN, Nurko S, Saps M, et al. The pediatric Rome IV criteria: what’s new? Expert Rev Gastroenterol Hepatol. 2017;11(3):193–201.
Martin CR; Osadchiy V; Kalani A; et al. The Brain-Gut-Microbiome Axis. Cell Mol Gastroenterol Hepatol. 2018;6(2):133–48.
Korpela K, Renko M, Paalanne N, Vänni P, Salo J, Tejesvi M, et al. Microbiome of the first stool after birth and infantile colic. Pediatr Res [Internet] 2020;88(5):776–83. Available from: https://doi.org/10.1038/s41390-0200804-y
Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N, et al. Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr. 2015 Jan;166(1):74–8.
Mi G-L, Zhao L, Qiao D-D, Kang W-Q, Tang M-Q, Xu J-K. Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. Antonie Van Leeuwenhoek. 2015 Jun;107(6):1547–53.
Pärtty A, Lehtonen L, Kalliomäki M, Salminen S, Isolauri E. Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trial. Pediatr Res. 2015 Oct;78(4):470–5.
Fatheree NY, Liu Y, Taylor CM, Hoang TK, Cai C, Rahbar MH, et al. Lactobacillus reuteri for infants with colic: a double-blind, placebo-controlled, randomized clinical trial. J Pediatr. 2017;191:170–8.
Turco R, Russo M, Bruzzese D, Staiano A. Efficacy of a partially hydrolysed formula, with reduced lactose content and with Lactobacillus reuteri DSM 17938 in infant colic: A double blind, randomised clinical trial. Clin Nutr. 2021 Feb;40(2):412–9.
Hizli S, Can D, Kiliç I, Örün E, Tunç T, Özkan H. Diagnosis and Treatment Approaches in Infantile Colic (IC): Results of a Survey Among Paediatricians in Turkey. Front Pediatr. 2021;9:779997.
Liu Y, Tran DQ, Rhoads JM. Probiotics in Disease Prevention and Treatment. J Clin Pharmacol. 2018 Oct;58 Suppl 10(Suppl 10):S164–79.
Freedman SB, Williamson-Urquhart S, Farion KJ, Gouin S, Willan AR, Poonai N, et al. Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis. N Engl J Med. 2018 Nov;379(21):2015–26.
Freedman SB, Schnadower D, Tarr PI. The Probiotic Conundrum: Regulatory Confusion, Conflicting Studies, and Safety Concerns. JAMA [Internet] 2020 Mar 3;323(9):823–4. Available from: https://doi.org/10.1001/jama.2019.22268
Dubois NE, Gregory KE. Characterizing the intestinal microbiome in infantile colic: findings based on an integrative review of the literature. Biol Res Nurs. 2016;18(3):307–15.
Sung V, D’Amico F, Cabana MD, Chau K, Koren G, Savino F, et al. Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis. Pediatrics [Internet] 2018 Jan 1;141(1):e20171811. Available from: https://doi.org/10.1542/peds.2017-1811
Jang A, Rod‐in W, Monmai C, Sohn M, Kim T, Jeon M, et al. Anti‐inflammatory potential of Lactobacillus reuteri LM1071 via eicosanoid regulation in LPS‐stimulated RAW264. 7 cells. J Appl Microbiol. 2022;133(1):67–75.
Qi SR, Cui YJ, Liu JX, Luo X, Wang HF. Lactobacillus rhamnosus GG components, SLP, gDNA and CpG, exert protective effects on mouse macrophages upon lipopolysaccharide challenge. Lett Appl Microbiol. 2020;70(2):118– 27.
Stinson LF, Boyce MC, Payne MS, Keelan JA. The not-so-sterile womb: evidence that the human fetus is exposed to bacteria prior to birth. Front Microbiol. 2019;1124.
Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. Sci Transl Med. 2014;6(237):237ra65-237ra65.
Dryl R, Szajewska H. Probiotics for management of infantile colic: a systematic review of randomized controlled trials. Arch Med Sci. 2018 Aug;14(5):1137–43.
Di Chio T, Sokollik C, Peroni DG, Hart L, Simonetti G, Righini-Grunder F, et al. Nutritional Aspects of Pediatric Gastrointestinal Diseases. Nutrients. 2021;13(6):2109.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
